Nimodipine

Nimodipine is a member of the dihydropyridine family of calcium channel blockers, the same broad chemical class as amlodipine and nifedipine, but it is distinguished by its lipophilic structure, which lets it cross the blood-brain barrier and act preferentially on the cerebral circulation ^[1][3]. Chemically it is a dihydropyridine dicarboxylate ester bearing a nitrophenyl group, and the marketed drug is a racemate containing equal parts of its two mirror-image forms.

The compound was patented in 1971 and entered medical use during the 1980s, with approval in Germany in 1985 and clearance by the United States Food and Drug Administration in 1988 ^[1]. Unlike most agents in its class, it was never developed chiefly for the routine treatment of high blood pressure; instead its niche became the neurological setting of subarachnoid hemorrhage.

Its central and best-established use is in aneurysmal subarachnoid hemorrhage, a serious bleeding stroke in which a ruptured aneurysm spills blood into the space surrounding the brain ^[3]. Survivors of the initial event remain at risk of delayed cerebral ischemia, a secondary decline linked to narrowing of cerebral arteries and other processes; nimodipine, started early and continued for roughly three weeks, has been shown to improve outcomes and is endorsed by management guidelines as the only pharmacologic therapy with proven benefit in this condition ^[1][2][3]. Notably, its clinical benefit is thought to reflect neuroprotection rather than a simple reversal of visible arterial spasm, since it improves outcomes without consistently abolishing angiographic vasospasm ^[2][3].

Beyond subarachnoid hemorrhage, nimodipine has been studied in other cerebrovascular and neurological settings. In reversible cerebral vasoconstriction syndrome, a disorder of recurrent thunderclap headache with transient artery narrowing, it appears to ease the headaches although it has not been shown to prevent the syndrome's strokes or bleeds ^[4]. Because standard nimodipine has pharmacokinetic drawbacks, including a short half-life and variable absorption, researchers have investigated longer-acting alternatives and intra-arterial or sustained-release approaches for vasospasm ^[1].

Nimodipine is a prescription medicine dispensed as oral capsules or tablets and as an oral liquid, with the liquid or capsule contents given by feeding tube when a patient cannot swallow ^[1]. It is widely available as a generic. Regulators require that it be given only by the oral or enteral route, and the product carries a prominent warning against any form of injection.

Nimodipine is prescription only and carries an important safety rule; it must be given by mouth or feeding tube, never by intravenous injection, because accidental IV use has caused deaths from severe cardiovascular collapse. The most common side effect is low blood pressure, which needs monitoring since it can reduce brain perfusion. Headache, flushing, nausea, and slow or fast heartbeat can also occur. It is broken down by the liver enzyme CYP3A4, so strong inhibitors such as certain antifungals and macrolide antibiotics can dangerously raise its levels, while strong inducers like rifampin can make it ineffective. Grapefruit juice should be avoided.

Polysorbate 80, a solubilizing excipient commonly used in nimodipine formulations, competitively inhibits nimodipine's CYP3A-mediated metabolism, increasing systemic exposure by 51% and decreasing clearance by 36.5% in animal models ^[23]. This is a pharmacokinetic interaction at the metabolic level. Beyond excipient interactions, nimodipine's interactions with other medications remain understudied in the published literature. No major drug-drug interactions with common co-medications were documented in recent peer-reviewed sources. Nimodipine activates pregnane X receptor, which could theoretically cause induction of metabolic enzymes and reduce levels of other CYP3A substrates, but clinical documentation of this effect is absent.

Checking a whole stack? Run it through interactions + stacks.

Nimodipine was developed by Bayer as a dihydropyridine calcium channel blocker deliberately tailored to act on the blood vessels of the brain rather than to serve as a general antihypertensive. The compound was patented in 1971, and after more than a decade of development it entered clinical use in the 1980s, receiving United States Food and Drug Administration approval in 1988 under the brand name Nimotop. Its defining property is a high lipid solubility that allows it to cross into the central nervous system and act with relative selectivity on the cerebral circulation.

Its principal approved role became the prevention of delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage, a dangerous complication of bleeding around the brain. A ready-to-use oral solution, Nymalize, was later approved in the United States in 2013 to ease administration, particularly for patients unable to swallow capsules. To this day it remains the only medication specifically approved to improve neurological outcomes after this type of stroke.

Nimodipine holds a distinguished and rather singular place in neurology and neurosurgery as the standard-of-care agent for aneurysmal subarachnoid hemorrhage, the only drug specifically approved to improve neurological recovery after this devastating form of bleeding. It is valued for its brain-selective action, made possible by a lipid solubility that lets it reach the cerebral arteries, and it is a fixture of intensive-care protocols worldwide.

One of the most intriguing aspects of its reputation is that it appears to help patients even when imaging shows no clear reversal of the arterial narrowing it was originally expected to counter, which has led clinicians to describe its benefit as broadly neuroprotective rather than purely a matter of widening vessels. Honesty demands acknowledging its limits; it can lower systemic blood pressure, which must be managed carefully, and researchers actively continue to seek agents with better pharmacokinetics. Nonetheless, its decades-long track record and unique approved indication keep it firmly established as a mainstay.